Patents Examined by Julie Wu
-
Patent number: 11795225Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.Type: GrantFiled: September 10, 2021Date of Patent: October 24, 2023Assignee: MedImmune LimitedInventors: Krista Lynne Kinneer, Gareth Charles Davies, David Gareth Rees, Jennifer Louise Percival-Alwyn, John Edward Andrews, Jon Chesebrough
-
Patent number: 11793867Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.Type: GrantFiled: December 18, 2018Date of Patent: October 24, 2023Assignee: BIONTECH US INC.Inventor: Vikram Juneja
-
Patent number: 11795236Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting positionType: GrantFiled: September 13, 2018Date of Patent: October 24, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11793835Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.Type: GrantFiled: November 23, 2022Date of Patent: October 24, 2023Assignee: Io Therapeutics, Inc.Inventors: Martin E. Sanders, Vidyasagar Vuligonda
-
Patent number: 11787858Abstract: Antibodies and antibody fragments that specifically bind to LILRB3 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB3 and methods of use thereof.Type: GrantFiled: December 22, 2017Date of Patent: October 17, 2023Assignee: Icahn School of Medicine at Mount SinaiInventors: Shu-Hsia Chen, Ping-Ying Pan
-
Patent number: 11779642Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.Type: GrantFiled: December 8, 2017Date of Patent: October 10, 2023Assignee: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
-
Patent number: 11759526Abstract: The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.Type: GrantFiled: May 25, 2018Date of Patent: September 19, 2023Assignees: MedImmune, LLC, The Regents Of The University Of CaliforniaInventors: Ronald James Christie, Changshou Gao, Andre Henri St. Amant, Javier Read de Alaniz
-
Patent number: 11738072Abstract: The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve the problem in the art that no technical scheme is available for generating lasting and high-effective anti-tumor immune responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex is formed by nucleic acid, especially replicable nucleic acid not expressing exogenous gene, and cationic biomaterial. The nucleic acid and the cationic biomaterial in the tumor vaccine according to the present invention have synergistic interactions on direct killing of tumor cells, and induction of the innate immune response and adaptive immune response of body against tumor. In addition, the prepared tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application.Type: GrantFiled: June 21, 2018Date of Patent: August 29, 2023Assignee: WestVac Biopharma Co., Ltd.Inventors: Xiawei Wei, Xia Zhao, Yuquan Wei, Zhiwei Zhao
-
Patent number: 11732048Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.Type: GrantFiled: November 2, 2021Date of Patent: August 22, 2023Assignees: Bergen Teknologioverføring AS, BerGenBio ASAInventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
-
Patent number: 11719699Abstract: Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.Type: GrantFiled: February 5, 2021Date of Patent: August 8, 2023Assignee: Ventana Medical Systems, Inc.Inventors: Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
-
Patent number: 11702480Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.Type: GrantFiled: November 17, 2017Date of Patent: July 18, 2023Assignee: The Regents of the University of CaliforniaInventors: Bin Liu, Namkyung Lee, Yang Su, Scott Bidlingmaier
-
Patent number: 11701428Abstract: Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.Type: GrantFiled: April 29, 2020Date of Patent: July 18, 2023Assignee: ImmunoGen, Inc.Inventors: Sharlene Adams, Callum M. Sloss, Patrick Zweidler-McKay
-
Patent number: 11702481Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.Type: GrantFiled: December 15, 2017Date of Patent: July 18, 2023Assignee: Bluefin Biomedicine, Inc.Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
-
Patent number: 11685769Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: July 2, 2021Date of Patent: June 27, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 11685790Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: August 11, 2021Date of Patent: June 27, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
-
Patent number: 11680042Abstract: The present invention provides a compound of formula (I), formula (II), formula (III), (IV) or a salt thereof, compositions and methods of making the compound, methods and reagents for measuring the compound, and kits using the same. The use of a compound of formula (I), formula (II), formula (III), or formula (IV) for assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifying a subject according to level of kidney function, and diagnosing or monitoring chronic kidney disease is also described.Type: GrantFiled: September 27, 2018Date of Patent: June 20, 2023Assignee: Metabolon, Inc.Inventor: Qibo Zhang
-
Patent number: 11680110Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.Type: GrantFiled: July 27, 2018Date of Patent: June 20, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Auer, Guy Georges, Stefan Klostermann, Wolfgang Schaefer
-
Patent number: 11666581Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.Type: GrantFiled: November 19, 2018Date of Patent: June 6, 2023Assignee: Genentech, Inc.Inventors: Thomas Pillow, Jack Sadowsky, Leanna Staben, Steven Staben, Binqing Wei, Ingrid Wertz, Pragya Adhikari, Nicole Blaquiere, Peter Dragovich, Wayne Fairbrother
-
Patent number: 11649291Abstract: Provided are variants of a chimeric anti-EGFR antibody. In various embodiments, the variants exhibit substantially improved thermostabilities and/or substantially higher levels of humanness, while retaining binding affinity near the parental level. The consistently high quality of the turnkey CoDAH designs, over a whole panel of variants, suggests that a computationally-directed approach encapsulates key determinants of antibody structure and function.Type: GrantFiled: May 24, 2017Date of Patent: May 16, 2023Assignee: Insmed IncorporatedInventors: Karl Edwin Griswold, Chris Bailey-Kellogg, Yoonjoo Choi
-
Patent number: 11649285Abstract: The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.Type: GrantFiled: August 3, 2017Date of Patent: May 16, 2023Assignee: BIO-TECHNE CORPORATIONInventors: Vassilios Kalabokis, Jinghua Wang, Guoping Wu, Jose Fernando Bazan, Christopher Carlin Valley